Clinical Trial Update: Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of cabozantinib (XL184) in adults with advanced malignancies, including lymphoma and thyroid carcinoma, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Thyroid Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Lymphoma, Cancer | Phase 1 | Status: COMPLETED